CTLA4 and neoplasm: Indeed, tumor gene expression signatures from many anti‐CTLA‐4/anti‐PD‐1 non‐responders indicate that other co‐inhibitory receptors should also be evaluated when considering optimal combinatorial checkpoint blockade strategies.151